LAUSR

Psoriasis is a multifactorial, chronic, auto‐ inflammatory disease, with a worldwide prevalence of around 2%, subtended by robust genetic predisposition and autoimmune pathogenic traits. The disease, mainly involving the skin and joints, is featured by erythemato‐squamous lesions, with a chronic relapsing course and relevant systemic comorbidities. Apremilast is a novel oral agent that has recently been made available to dermatologists for the treatment of moderate‐to‐severe plaque psoriasis and psoriatic arthritis. Although it is considered as relatively safe molecule with few contraindications, experience with Apremilast in the real‐world setting for cancer patients with moderate‐to‐severe plaque psoriasis is lacking. Hence, we report the real‐life experience in patients with psoriasis and a history of cancer who underwent treatment with Apremilast for 104 weeks.